These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20176047)

  • 1. Inhibitors of phosphatidylinositol-3-kinase in cancer therapy.
    Ihle NT; Powis G
    Mol Aspects Med; 2010 Apr; 31(2):135-44. PubMed ID: 20176047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the phosphoinositide 3-kinase pathway in cancer.
    Liu P; Cheng H; Roberts TM; Zhao JJ
    Nat Rev Drug Discov; 2009 Aug; 8(8):627-44. PubMed ID: 19644473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.
    Klempner SJ; Myers AP; Cantley LC
    Cancer Discov; 2013 Dec; 3(12):1345-54. PubMed ID: 24265156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New phosphatidylinositol 3-kinase inhibitors for cancer.
    Bowles DW; Jimeno A
    Expert Opin Investig Drugs; 2011 Apr; 20(4):507-18. PubMed ID: 21395485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PI3K-AKT pathway for cancer therapy.
    Lu Y; Wang H; Mills GB
    Rev Clin Exp Hematol; 2003 Jun; 7(2):205-28. PubMed ID: 14763163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the PI3K signaling pathway in cancer.
    Wong KK; Engelman JA; Cantley LC
    Curr Opin Genet Dev; 2010 Feb; 20(1):87-90. PubMed ID: 20006486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
    Jabbour E; Ottmann OG; Deininger M; Hochhaus A
    Haematologica; 2014 Jan; 99(1):7-18. PubMed ID: 24425689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
    Krystal GW; Sulanke G; Litz J
    Mol Cancer Ther; 2002 Sep; 1(11):913-22. PubMed ID: 12481412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Status of PI3K inhibition and biomarker development in cancer therapeutics.
    Markman B; Atzori F; Pérez-García J; Tabernero J; Baselga J
    Ann Oncol; 2010 Apr; 21(4):683-691. PubMed ID: 19713247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the PI3K-Akt pathway in kidney cancer.
    Park JY; Lin PY; Weiss RH
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):863-70. PubMed ID: 17555396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020).
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Expert Opin Ther Pat; 2021 Oct; 31(10):877-892. PubMed ID: 33970742
    [No Abstract]   [Full Text] [Related]  

  • 12. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
    Yuan J; Mehta PP; Yin MJ; Sun S; Zou A; Chen J; Rafidi K; Feng Z; Nickel J; Engebretsen J; Hallin J; Blasina A; Zhang E; Nguyen L; Sun M; Vogt PK; McHarg A; Cheng H; Christensen JG; Kan JL; Bagrodia S
    Mol Cancer Ther; 2011 Nov; 10(11):2189-99. PubMed ID: 21750219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PI3K pathway as drug target in human cancer.
    Courtney KD; Corcoran RB; Engelman JA
    J Clin Oncol; 2010 Feb; 28(6):1075-83. PubMed ID: 20085938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.
    Kong DX; Yamori T
    Acta Pharmacol Sin; 2010 Sep; 31(9):1189-97. PubMed ID: 20729870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart.
    McMullen JR; Jay PY
    Cell Cycle; 2007 Apr; 6(8):910-3. PubMed ID: 17404510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.
    Ihle NT; Powis G
    Mol Cancer Ther; 2009 Jan; 8(1):1-9. PubMed ID: 19139107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PI3K signaling in cancer: Challenges and advances.
    De Santis MC; Gulluni F; Campa CC; Martini M; Hirsch E
    Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):361-366. PubMed ID: 30946868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the PI3K signaling pathway in cancer therapy.
    Bartholomeusz C; Gonzalez-Angulo AM
    Expert Opin Ther Targets; 2012 Jan; 16(1):121-30. PubMed ID: 22239433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy.
    Chen YL; Law PY; Loh HH
    Curr Med Chem Anticancer Agents; 2005 Nov; 5(6):575-89. PubMed ID: 16305480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
    Curigliano G; Shah RR
    Drug Saf; 2019 Feb; 42(2):247-262. PubMed ID: 30649751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.